永安药业
(002365)
| 流通市值：40.89亿 | | | 总市值：49.06亿 |
| 流通股本：2.46亿 | | | 总股本：2.95亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 577,148,711.33 | 367,377,098.49 | 171,153,602.96 | 838,814,941.7 |
| 营业收入 | 577,148,711.33 | 367,377,098.49 | 171,153,602.96 | 838,814,941.7 |
| 二、营业总成本 | 586,972,011.53 | 373,906,890.49 | 184,150,029.42 | 798,694,169.91 |
| 营业成本 | 478,752,909.74 | 309,288,489.16 | 154,528,544 | 671,116,742.34 |
| 税金及附加 | 7,525,479.51 | 5,115,003.65 | 2,911,591.95 | 9,445,248.41 |
| 销售费用 | 31,798,297.87 | 14,587,095.68 | 4,415,026.54 | 17,277,364.95 |
| 管理费用 | 44,042,372.41 | 29,255,363.87 | 15,216,294.82 | 73,352,046.49 |
| 研发费用 | 26,082,917.32 | 17,358,750.95 | 8,417,652.08 | 36,974,497.81 |
| 财务费用 | -1,229,965.32 | -1,697,812.82 | -1,339,079.97 | -9,471,730.09 |
| 其中:利息费用 | 738,453.53 | 520,720.37 | 225,867.72 | 585,858.91 |
| 其中:利息收入 | 923,207.65 | 633,205.18 | 280,337.38 | 1,096,356.27 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 85,800.14 | 2,004,491.16 | -2,371,888.97 | 4,431,333.86 |
| 加:投资收益 | 25,322,485.07 | 11,461,930.22 | 5,189,100.12 | 39,679,131.94 |
| 资产处置收益 | 52,495.68 | 32,631.44 | 6,694.64 | -326,208.7 |
| 资产减值损失(新) | -822,527.84 | -444,891 | - | -18,286,031.52 |
| 信用减值损失(新) | 822,783.62 | 1,470,540.52 | 1,743,207.89 | -357,213.64 |
| 其他收益 | 2,599,789.12 | 1,701,484.47 | 818,582.24 | 7,671,601.16 |
| 四、营业利润 | 18,237,525.59 | 9,696,394.81 | -7,610,730.54 | 72,933,384.89 |
| 加:营业外收入 | 589,194.56 | 295,984.95 | 28,826.58 | 1,967,662.09 |
| 减:营业外支出 | 806,265.26 | 511,411.57 | 209,048.09 | 4,040,314.61 |
| 五、利润总额 | 18,020,454.89 | 9,480,968.19 | -7,790,952.05 | 70,860,732.37 |
| 减:所得税费用 | 1,678,334.1 | 924,809.5 | -1,097,010.81 | 11,153,027.59 |
| 六、净利润 | 16,342,120.79 | 8,556,158.69 | -6,693,941.24 | 59,707,704.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 16,342,120.79 | 8,556,158.69 | -6,693,941.24 | 59,707,704.78 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 25,496,259.56 | 12,495,723.72 | -4,367,181.24 | 61,766,022.21 |
| 少数股东损益 | -9,154,138.77 | -3,939,565.03 | -2,326,760 | -2,058,317.43 |
| 扣除非经常损益后的净利润 | 5,184,418.3 | 2,285,336.05 | -6,669,596.75 | 26,758,071.75 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.04 | -0.02 | 0.21 |
| (二)稀释每股收益 | 0.09 | 0.04 | -0.02 | 0.21 |
| 八、其他综合收益 | -86,818.37 | -31,790.91 | -10,617.52 | -1,869,850.36 |
| 归属于母公司股东的其他综合收益 | -86,818.37 | -31,790.91 | -10,617.52 | -1,869,850.36 |
| 九、综合收益总额 | 16,255,302.42 | 8,524,367.78 | -6,704,558.76 | 57,837,854.42 |
| 归属于母公司股东的综合收益总额 | 25,409,441.19 | 12,463,932.81 | -4,377,798.76 | 59,896,171.85 |
| 归属于少数股东的综合收益总额 | -9,154,138.77 | -3,939,565.03 | -2,326,760 | -2,058,317.43 |
| 公告日期 | 2025-10-30 | 2025-08-28 | 2025-04-29 | 2025-04-10 |
| 审计意见(境内) | | | | 标准无保留意见 |